26 February 2016 - Servier today announced that the CHMP of the EMA has adopted a positive opinion, recommending Lonsulf (trifluridine/tipiracil) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.

For more details, go to: http://www.servier.com/content/servier-receives-positive-chmp-opinion-lonsurf®-trifluridinetipiracil-refractory-metastatic